Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE-CMD Part 1 acute drug testing in coronary microvascular dysfunction
ACTRN12625001179426Phase 4Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clevidipine, esmolol, epoprostenol, nitroglycerin, sildenafil and 1 more in Coronary Small Vessel Disease (CMD) and angina pectoris (2 arms), sponsored by Sydney Local Health District. Primary endpoint: Change in index of microvascular resistance. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
clevidipineesmololepoprostenolnitroglycerinsildenafil
03
Conditions
Coronary Small Vessel Disease (CMD)angina pectoris
Beyond the preview
Go deeper on ACTRN12625001179426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001179426.